These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

614 related items for PubMed ID: 23775496

  • 1. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
    Shiota M, Kashiwagi E, Yokomizo A, Takeuchi A, Dejima T, Song Y, Tatsugami K, Inokuchi J, Uchiumi T, Naito S.
    Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
    [Abstract] [Full Text] [Related]

  • 2. Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression.
    Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, Masubuchi D, Eto M, Uchiumi T, Naito S.
    Oncogene; 2010 Jan 14; 29(2):237-50. PubMed ID: 19802001
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
    Shiota M, Itsumi M, Takeuchi A, Imada K, Yokomizo A, Kuruma H, Inokuchi J, Tatsugami K, Uchiumi T, Oda Y, Naito S.
    Endocr Relat Cancer; 2015 Dec 14; 22(6):889-900. PubMed ID: 26311513
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK, Kyprianou N.
    Adv Cancer Res; 2015 Dec 14; 127():123-58. PubMed ID: 26093899
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer.
    Shiota M, Song Y, Takeuchi A, Yokomizo A, Kashiwagi E, Kuroiwa K, Tatsugami K, Uchiumi T, Oda Y, Naito S.
    J Urol; 2012 Feb 14; 187(2):707-14. PubMed ID: 22177207
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
    Komura K, Jeong SH, Hinohara K, Qu F, Wang X, Hiraki M, Azuma H, Lee GS, Kantoff PW, Sweeney CJ.
    Proc Natl Acad Sci U S A; 2016 May 31; 113(22):6259-64. PubMed ID: 27185910
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer.
    Shiota M, Yokomizo A, Takeuchi A, Imada K, Kashiwagi E, Song Y, Inokuchi J, Tatsugami K, Uchiumi T, Naito S.
    Clin Cancer Res; 2014 Feb 15; 20(4):951-61. PubMed ID: 24352647
    [Abstract] [Full Text] [Related]

  • 15. Molecular complexity of taxane-induced cytotoxicity in prostate cancer cells.
    Mang J, Merkle K, Heller M, Schüler J, Tolstov Y, Li J, Hohenfellner M, Duensing S.
    Urol Oncol; 2017 Jan 15; 35(1):32.e9-32.e16. PubMed ID: 27692847
    [Abstract] [Full Text] [Related]

  • 16. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
    Thelen P, Heinrich E, Bremmer F, Trojan L, Strauss A.
    Prostate; 2013 Nov 15; 73(15):1699-709. PubMed ID: 23868789
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.